← Back to Home

Chronic Hepatitis B Control After Stopping Treatment Comes Within Reach: FDA Approves Bepirovirsen With Eligibility and Safety Requirements

In two Phase 3 trials, approximately 19% of patients receiving the new therapy achieved a functional cure; however, after completing the 24-week injection course, patients must continue oral antiviral medication and undergo assessment before potentially stopping all treatment.

By SURL BioNews

For many people with chronic hepatitis B, controlling the virus means taking medication continuously for years. Now, a new therapy offers some patients the possibility of maintaining control after stopping treatment. On October 20, the U.S. Food and Drug Administration (FDA) approved GSK’s Hibsago (bepirovirsen) for use alongside existing antiviral medication, making it the first antisense oligonucleotide drug approved in the United States to treat chronic hepatitis B. However, this path toward stopping treatment comes with clear eligibility criteria and strict safety monitoring.

Approval is limited to adults without cirrhosis who have received nucleoside or nucleotide analogue therapy for at least six months, have suppressed blood HBV DNA levels, and have a hepatitis B surface antigen (HBsAg) level no higher than 3,000 IU/mL, as confirmed by an FDA-authorized test. The FDA also authorized Roche’s Elecsys HBsAg II quant II RxDx companion diagnostic to help select patients and monitor treatment. In other words, controlling viral load is only the starting point; quantitative surface antigen results also determine eligibility for treatment.

Bepirovirsen targets viral RNA to reduce the production of viral proteins, including surface antigen. B-Well 1 and B-Well 2, the trials supporting approval, were randomized, double-blind, placebo-controlled Phase 3 trials. Pooled results showed that 233 of the 1,220 patients receiving bepirovirsen, approximately 19%, achieved a functional cure, compared with none of the 614 patients in the placebo group. Here, “functional cure” means that surface antigen remains undetectable and HBV DNA remains below the lower limit of quantification at least 24 weeks after stopping all hepatitis B treatment. It describes disease control after treatment cessation and cannot be interpreted directly as complete elimination of the virus from the body.

The treatment timeline is also longer than “six months of injections before stopping medication.” Under the FDA-approved regimen, bepirovirsen is administered by subcutaneous injection for up to 24 weeks alongside the patient’s existing antiviral medication. That medication must continue for at least 24 weeks after the final injection, followed by an assessment of whether treatment can be stopped based on health status and test results. Across the two trials, 24% of patients in the new drug group met the criteria for stopping their existing medication, while 19% ultimately reached the primary efficacy endpoint. These percentages represent different stages and should not be conflated.

Longer follow-up provides further indications of the durability of efficacy. According to GI & Hepatology News, citing updated prescribing information, 211 of the 233 patients who initially achieved a functional cure maintained their response at week 96, corresponding to 48 weeks after stopping all hepatitis B treatment. This maintenance rate of approximately 91% uses patients who had previously achieved the endpoint as its denominator, rather than all patients who received the drug. Whether the response can persist for years requires longer-term follow-up.

Safety is another aspect of this new option that cannot be overlooked. The prescribing information carries a boxed warning for hepatitis flares during treatment and thrombocytopenia, the latter of which can occur suddenly and be life-threatening. Liver function and platelet counts must be checked before and during treatment, with platelet monitoring at least weekly. Additional warnings address worsening kidney function and severe inflammatory and immune reactions. These requirements mean that even a finite treatment course requires intensive medical follow-up.

This approval gives a clearly defined group of patients a greater possibility of moving from long-term viral suppression to disease control after stopping treatment, but it has yet to reshape the treatment outlook for all people with chronic hepatitis B. The trials did not include patients with cirrhosis, and efficacy has not been established in those whose surface antigen levels exceed the approved threshold. Even eligible patients who successfully stop treatment remain at risk of acute exacerbations of hepatitis B, and the prescribing information requires close monitoring for at least one year. The value of the new therapy will depend on how long its efficacy lasts and whether clinicians can manage the risks while pursuing the opportunity to stop treatment.

References

  1. GSK
  2. U.S. Food and Drug Administration
  3. U.S. Food and Drug Administration
  4. GI & Hepatology News